BNT162b2 mRNA新冠疫苗在既往COVID-19患者中的耐受性:病例对照研究
该研究通过匿名自我报告调查,比较了有既往COVID-19病史者(n=61)与无病史者(n=1987)接种第一剂BNT162b2疫苗后21-28天的安全性与耐受性。结果显示,既往COVID-19组全身反应发生率更高(45.9% vs 29.7%,p=0.01),乏力、头痛、发热更常见,且严重程度更高(p=0.03),但总体耐受性良好。
要点
- 既往COVID-19者接种BNT162b2后全身反应发生率45.9%,高于无病史者的29.7%。
- 乏力、头痛、发热在既往COVID-19组显著更常见,且严重程度更高。
- 尽管副作用风险较高,但整体耐受性良好。
核心结论
- 既往SARS-CoV-2感染者接种BNT162b2疫苗后副作用风险更高,但总体耐受性良好。
研究设计与样本
- 病例对照研究,采用匿名自我报告调查,在两家接种中心于第一剂疫苗接种后21至28天完成。
- 既往COVID-19病史组61人,无既往史组1987人。
主要发现
- 既往COVID-19组全身反应发生率为45.9%,无病史组为29.7%(p=0.01)。
- 乏力发生率25.6% vs 15.2%(p=0.045),头痛19.7% vs 9.3%(p=0.01),发热6.5% vs 0.9%(p=0.003)。
- 既往COVID-19组严重程度分级高于无病史组(p=0.03)。
临床怎么用
- 对既往COVID-19感染者接种BNT162b2疫苗时,应告知其全身反应可能更常见且程度更重,但整体耐受性良好。
局限性
- 研究采用匿名自我报告调查,可能存在报告偏倚。
- 既往COVID-19组样本量较小(n=61)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Studies evaluating BNT162b2 mRNA Covid-19 vaccine safety excluded subjects with a previous history of COVID-19 infection. The aim of our study was to focus on the tolerance of this vaccine this population. METHODS: An anonymous self-reporting survey related to safety and tolerance of vaccine was completed by subjects 21 to 28 days after the first vaccine dose in two vaccination centers. RESULTS: Subjects with prior COVID-19 disease history (n = 61) had higher systemic reactions than subjects without any previous history (n = 1987) (45.9% vs 29.7%, p = 0.01). Asthenia, headache and fever were significantly more frequent in COVID-19 + group than negative group (25.6% vs 15.2% p = 0.045, 19.7% vs 9.3% p = 0.01, 6.5% vs 0.9% p = 0.003 respectively). Grade of severity was higher in COVID-19 + than in COVID-19 - group (p = 0.03). CONCLUSION: Our study confirms a higher risk of side effects in patients with preexisting SARS-CoV-2 disease but with a good overall tolerance.
引用
- Baldolli A, Michon J, Appia F, et al. Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study. Vaccine. 2021. PMID: 34210574. doi:10.1016/j.vaccine.2021.06.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。